Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.

Article  PubMed  CAS  Google Scholar 

Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019. https://doi.org/10.1183/13993003.00250-2019.

Article  PubMed  Google Scholar 

Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med. 2022;43(4):697–716.

Article  PubMed  Google Scholar 

Wallace RJ Jr., Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002;46(10):3164–7.

Article  PubMed  CAS  Google Scholar 

Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810–8.

Article  PubMed  CAS  Google Scholar 

Maurer FP, Bruderer VL, Castelberg C, Ritter C, Scherbakov D, Bloemberg GV, Bottger EC. Aminoglycoside-modifying enzymes determine the innate susceptibility to aminoglycoside antibiotics in rapidly growing mycobacteria. J Antimicrob Chemother. 2015;70(5):1412–9.

Article  PubMed  CAS  Google Scholar 

Lefebvre AL, Le Moigne V, Bernut A, Veckerle C, Compain F, Herrmann JL, Kremer L, Arthur M, Mainardi JL. Inhibition of the beta-lactamase bla(Mab) by avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.02440-16.

Article  PubMed  PubMed Central  Google Scholar 

Rominski A, Roditscheff A, Selchow P, Bottger EC, Sander P. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother. 2017;72(2):376–84.

Article  PubMed  CAS  Google Scholar 

Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST, Nash K, Parodi N, Strong A, Gee M, Smith T, Wallace RJ Jr. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol. 2015;53(4):1211–5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, Bottger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):905–13.

Article  PubMed  PubMed Central  Google Scholar 

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71(Suppl 1):i1-22.

Article  PubMed  Google Scholar 

Choi H, Kim SY, Kim DH, Huh HJ, Ki CS, Lee NY, Lee SH, Shin S, Shin SJ, Daley CL, Koh WJ. Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017;61(10):10–1128.

Article  Google Scholar 

Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53(4):1367–76.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, Lee K, Lee SH, Daley CL, Kim S, Jeong BH, Jeon K, Koh WJ. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012;186(9):917–25.

Article  PubMed  CAS  Google Scholar 

Maurer FP, Castelberg C, Quiblier C, Bottger EC, Somoskovi A. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother. 2014;69(6):1559–63.

Article  PubMed  CAS  Google Scholar 

Schildkraut JA, Pennings LJ, Ruth MM, de Brouwer AP, Wertheim HF, Hoefsloot W, de Jong A, van Ingen J. The differential effect of clarithromycin and azithromycin on induction of macrolide resistance in Mycobacterium abscessus. Future Microbiol. 2019;14:749–55.

Article  PubMed  CAS  Google Scholar 

Richard M, Gutierrez AV, Kremer L. Dissecting erm(41)-mediated macrolide-inducible resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64(2):10–128.

Article  Google Scholar 

Kim HY, Kim BJ, Kook Y, Yun YJ, Shin JH, Kook YH. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol. 2010;54(6):347–53.

Article  PubMed  CAS  Google Scholar 

Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, Yano S, Shigeto E, Kuraoka T, Kajiki A, Kobashi Y, Kokubu F, Sato A, Yoshida S, Iwamoto T, Saito H. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012;50(11):3556–61.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Roux AL, Catherinot E, Soismier N, Heym B, Bellis G, Lemonnier L, Chiron R, Fauroux B, Le Bourgeois M, Munck A, Pin I, Sermet I, Gutierrez C, Veziris N, Jarlier V, Cambau E, Herrmann JL, Guillemot D, Gaillard JL. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. J Cyst Fibros. 2015;14(1):63–9.

Article  PubMed  Google Scholar 

Blondiaux N, Moune M, Desroses M, Frita R, Flipo M, Mathys V, Soetaert K, Kiass M, Delorme V, Djaout K, Trebosc V, Kemmer C, Wintjens R, Wohlkonig A, Antoine R, Huot L, Hot D, Coscolla M, Feldmann J, Gagneux S, Locht C, Brodin P, Gitzinger M, Deprez B, Willand N, Baulard AR. Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. Science. 2017;355(6330):1206–11.

Article  PubMed  CAS  Google Scholar 

Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. FEMS Microbiol Rev. 2019;43(5):490–516.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dubee V, Bernut A, Cortes M, Lesne T, Dorchene D, Lefebvre AL, Hugonnet JE, Gutmann L, Mainardi JL, Herrmann JL, Gaillard JL, Kremer L, Arthur M. Beta-lactamase inhibition by avibactam in Mycobacterium abscessus. J Antimicrob Chemother. 2015;70(4):1051–8.

Article  PubMed  CAS  Google Scholar 

Aziz DB, Go ML, Dick T. Rifabutin suppresses inducible clarithromycin resistance in Mycobacterium abscessus by blocking induction of whiB7 and erm41. Antibiot (Basel). 2020;9(2):72.

Article  CAS  Google Scholar 

Cavalier JF, Spilling CD, Durand T, Camoin L, Canaan S. Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery. Eur J Med Chem. 2021;209:112908.

Article  PubMed  CAS  Google Scholar 

Madani A, Ridenour JN, Martin BP, Paudel RR, Abdul Basir A, Le Moigne V, Herrmann JL, Audebert S, Camoin L, Kremer L, Spilling CD, Cavalier JF. Cyclipostins and cyclophostin analogues as multitarget inhibitors that impair growth of Mycobacterium abscessus. ACS Infect Dis. 2019;5(9):1597–608.

Article  PubMed  CAS  Google Scholar 

Nguyen PC, Delorme V, Benarouche A, Martin BP, Paudel R, Gnawali GR, Madani A, Puppo R, Landry V, Kremer L, Brodin P, Spilling CD, Cavalier JF, Canaan S. Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. Sci Rep. 2017;7(1):11751.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen PC, Madani A, Santucci P, Martin BP, Paudel RR, Delattre S, Herrmann JL, Spilling CD, Kremer L, Canaan S, Cavalier JF. Cyclophostin and cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases. Int J Antimicrob Agents. 2018;51(4):651–4.

Article  PubMed  CAS